Complete Growth Inhibition of Human Cancer Xenografts in Nude Mice by Treatment with 20- (5) -Camptothecin

Cancer Research

Volumn 51, Issue 11, 1991, Pages 3052-3055

  Giovanella, Beppino C ^a   Hinz, Hellmuth R ^a   Kozielski, Anthony J ^a   Stehlin, John S ^a   Silber, Robert ^b   Potmesil, Milan ^b  

^a St Joseph's Medical Center Houston   (United States)

^b Kaplan Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN;

ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; DRUG THERAPY; HUMAN; HUMAN TISSUE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TOXICITY; TUMOR XENOGRAFT;

ANIMAL; CAMPTOTHECIN; DRUG ADMINISTRATION SCHEDULE; DRUG SCREENING ASSAYS, ANTITUMOR; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED;

EID: 0025912553     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Wall, M., Wani, M. C., Cooke, C. E., Palmer, K. H., McPhall, A. T., and Slim, G. A. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and antitumor inhibitor from Campto-theca acuminata. J. Am. Chem. Soc., 88: 3888-3890, 1966.
2. Gottlieb, J. A., Guarino, A. M., Call, J. B., Oliverio, V. T., and Block, J. B. Preliminary pharmacological and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother. Rep., 54: 461-470, 1970.
3. Muggia, F. M., Creaven, P. J., Hansen, H. H., Cohen, M. N., and Selawry, D. S. Phase 1 clinical trials of weekly and daily treatment with camptothecin (NSC 100880). Correlation with clinical studies. Cancer Chemother. Rep., 56:515-521; 1972.
4. Gottlieb, J. A. and Luce, J. K. Treatment of malignant melanoma with camptothecin (NSC 100800). Cancer Chemother. Rep., 56: 103-105, 1972.
5. Moertel, C. G., Schutt, A. J., Reitemeier, R. J., and Hahn, R. G. Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep., 56: 95-101, 1972.
6. Potmesil, M., Giovanella, B. C., Liu, L. F., Wall, M. E., Silber, R., Stehlin, J. S., Hsiang, Y-H., and Wani, M. C. Preclinical studies of DNA topoisomerase I-targeted 9-amino and 10,11-methylenedioxy camptothecins. In: M. Potmesil and K. W. Kohn (eds.), DNA Topoisomerases in Cancer. New York: Oxford University Press, in press, 1991.
7. Wani, M. C., Nicholas, A. W., and Wall, M. E. Plant antitumor agents. Synthesis and antileukemia activity of camptothecin analogues. J. Med. Chem., 29: 2358-2363; 1986.
8. Wani, M. C., Nicholas, A. W., Manikumar, G., and Wall, M. E. Plant antitumor agents. 25. Total synthesis and antileukemic activity of ring A substituted camptothecin analogues. Structure activity correlations. J. Med. Chem. 30: 1774-1779, 1987.
9. Hsiang, Y-H., Hertzberg, R., Hecht, S., and Liu, L. F. Camptothecin induced protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 260: 14873-14878, 1985.
10. Hsiang, Y-H. and Liu, L. F. Identification and mammalian topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res., 48: 1722-1726, 1988.
11. Jaxel, C, Kohn, K. W., Wani, M. C., Wall, M. E., and Pommier, Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase-I. Evidence for a specific receptor site and for a relation to antitumor activity. Cancer Res., 49: 1465-1469, 1989.
12. Hsiang, Y-H., Liu, L. F., Wall, M. E., Wani, M. C., Nicholas, A. W., Manikumar, G., Kirschenbaum, S., Silber, R., and Potmesil, M. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res., 49:4385-4389, 1989.
13. Giovanella, B. C., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., and Potmesil, M. Highly effective topoisomerase-I targeted chemotherapy of human colon cancer in xenografts. Science (Washington DC), 246: 1046-1048, 1989.
14. Potmesil, M., Wall, M. E., Wani, M. C., Silber, R., Stehlin, J. S., and Giovanella, B. C. 9-Amino (NSC 629971, 9AC] and 10,11-methylenedioxy [NSC 606174. 10.11-MDC] camptothecins in the treatment of human cancer maligxenografts. Proc. Am. Assoc. Cancer Res., 32: 337. 1991.
15. Giovanella. B. C., Stehlin. J. S., Shepard. R. C., and Williams. L. J. Correlation between response to chemotherapy of human tumors in patients and in nude mice. Cancer (Phila.). 52: 1146-1152, 1983.
16. Lockshin. A., Giovanella, B. C., de Ipolyi, P. D., Williams. L. J., Jr. Mendoza, J. T., Vim, S. O., and Stehlin, J. S., Jr. Exceptional lethality for nude mice of cells derived from a primary human melanoma. Cancer Res., 45: 345-350, 1985.
17. Giovanella. B. C., and Stehlin. J. S. Heterotransplantation of human malig nant tumors in “nude” thymusless mice. I. Breeding and maintenance of “nude” mice. J. Nati. Cancer Inst., 51:615-619, 1973.
18. Boren. E., Winograd, B., Fodstad. O., et al. Preclinical phase II studies in human tumour lines: A European multicentre study. Eur. J. Cancer Clin., Oncol. 24: 567-573, 1988.
19. Winograd. B., Boren. E., Lobbezoo, M. W., et al. Human tumor xenografts in the nude mouse and their value as test models in anticancer drug development. In Vivo (Athens). 1: 1-14. 1987.